LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor

J Med Chem. 2013 Jul 25;56(14):5673-4. doi: 10.1021/jm401005u.

Jianyong Chen ¹, Cheng Jiang, Shaomeng Wang

Affiliations

Affiliation

1 Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, University of Michigan , Ann Arbor, Michigan 48109, United States.

PMID: 23837797 DOI: 10.1021/jm401005u

Products

Cat. No.

Product Name

Description

Target

Research Area
HY-15656

Ceritinib

99.98%, Insulin Receptor Inhibitor

Anaplastic lymphoma kinase (ALK); Insulin Receptor; IGF-1R

Endocrinology; Cancer
HY-15656R

Ceritinib (Standard)

Insulin Receptor Inhibitor

Anaplastic lymphoma kinase (ALK); Insulin Receptor; IGF-1R

Endocrinology; Cancer

MedChemExpress Magic Cece

MedChemExpress: Contact Us; About Us; Headquarters; Distributors; Statement on False Report; Careers

Customer Support: Technical Support; Service; Ordering Information; Easy Return; Shipping Rates & Policies; Intellectual Property Promise

Resources: Free Sample; Resources; Molarity Calculator; Dilution Calculator; Terms & Conditions; Reconstitution Calculator; Specific Activity Calculator

Subscribe to our E-newsletter

Name
Email *

	Sorry, but the email address you supplied was invalid.

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.

Copyright © 2013-2024 MedChemExpress. All Rights Reserved.: Site Map Privacy Policy

Join with us